Healthy Aging Health Center
This article is from the WebMD Feature Archive
Older Drivers: The Car Key Decision
When a police cruiser drove up to the Casa del Rio retirement community in Peoria, Ariz., assistant manager Debra Gauthier wasn't a bit surprised to see Mr. C, as she calls him, sitting in the back seat. The 93-year-old resident was being brought home by the authorities because he had parked his car in Phoenix and lost it. And it wasn't the first time he'd had a memory lapse on the road.
Fearful that Mr. C would crash while driving the next time, Gauthier and her co-workers made a plan. When the police returned his blue Ford Taurus, a Casa del Rio staff member parked it far from Mr. C's normal space, disconnected the battery, and held on to his keys.
"But he found it," Gauthier says. "He had it fixed and started driving again with an extra set of keys." He didn't even remember that he had lost the car. When she told Mr. C he shouldn't be driving, he became furious.
The to-drive or not-to-drive question will loom for more and more American families. In 2000, 1 in 10 drivers was over 70 -- a 36% increase from 1990, according to the National Highway Traffic Safety administration.
While some older drivers remain competent, others do not. In 2001, people 65 and older made up 16% of the driving age population and accounted for 16% of fatal vehicle crashes, according to the Insurance Institute for Highway Safety. By 2030, elderly people will make up 25% of all drivers and be involved in 25% of fatal accidents, the institute says.
The Legal Approach
Deciding which older drivers are safe on the road and which are dangerous is no small task. The best way to keep drivers like Mr. C off the road, some say, are stringent state laws that require more frequent testing of all older drivers, regardless of their driving records. But others see that approach as "ageist."
Nonetheless, 13 states require older drivers to renew their licenses more frequently than younger drivers, according to the Insurance Institute for Highway Safety. In Illinois, for instance, once drivers reach age 75 they must take a road test every time they renew their license. They must renew every two years starting at age 81 and every year after age 87.
Other states with special provisions for older drivers include Arizona, Colorado, Hawaii, Idaho, Indiana, Iowa, Kansas, Maine, Missouri, Montana, New Mexico, and Rhode Island.
The Fix-It Approach
Others suggest a more humanistic approach: helping older drivers stay on the road whenever possible by correcting physical problems. For instance, obstacles that once seemed incompatible with driving, such as cataracts and slow reaction times, now may be overcome.
Older drivers with a cataract, an opaque clouding of the eye's lens, are more than twice as likely to have been in a crash in recent years than those without them.
Indication
Uroxatral® (alfuzosin HCl 10 mg extended-release tablets) is an alpha1-blocker for the treatment of the signs and symptoms of BPH.
Important Safety Information
Do not take UROXATRAL if you have liver problems or if you are taking antifungal drugs like ketoconazole or itraconazole, or HIV drugs like ritonavir.
UROXATRAL can cause a sudden drop in blood pressure, especially when starting treatment. This may lead to fainting, dizziness, and lightheadedness. Do not drive, operate machinery, or do any dangerous activity until you know how UROXATRAL will affect you. This is especially important if you already have a problem with low blood pressure or take medicines to treat high blood pressure. There may be an increased risk of low blood pressure and fainting when taking UROXATRAL in combination with blood pressure medication or nitrates, or erectile dysfunction medication.
If considering cataract surgery (clouding of the eyes), tell your eye surgeon that you are currently taking UROXATRAL or have previously been treated with an alpha-blocker.
Before taking UROXATRAL, tell your doctor if you have kidney problems.
Also, tell your doctor if you or any family member(s) have or take medications for a rare heart condition known as congenital prolongation of the QT interval.
BPH and prostate cancer can cause the same symptoms. However, UROXATRAL is not a treatment for prostate cancer.
The most common side effects with UROXATRAL are dizziness, upper respiratory tract infection, headache, and tiredness.
Please see UROXATRAL full prescribing information.
VIVELLE-DOT (estradiol transdermal system) IS AVAILABLE BY PRESCRPTION ONLY.
INDICATION
Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman's ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.
IMPORTANT SAFETY INFORMATION
Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).
Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).
Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.
The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.
You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information for Vivelle-Dot.


